And right now, multiple potential catalysts could fuel a vertical chart move in the near term for ALBT. They are:
No. 1 ALBT Potential Catalyst - Signing Of Game-Changing, Transformative Definitive Agreement For Acquisition
Avalon GloboCare Signs Definitive Agreement for Transformational Acquisition of Leading Laboratory with 2021 Unaudited Revenue in Excess of $25Mn
FREEHOLD, N.J., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. ("Avalon" or the "Company"), a leading global developer of innovative cell-based technologies and therapeutics, today announced that it has signed a definitive acquisition agreement (the "Acquisition Agreement") to acquire a 60% interest in Laboratory Services MSO, LLC, a premier reference laboratory. In connection with the transaction, and to reflect the expanded focus on lab testing and services, Avalon will be changing its ticker symbol from "AVCO" to "ALBT." ...
Headquartered in Costa Mesa California, Laboratory Services provides a broad portfolio of diagnostic tests including dr-ug testing, toxicology, and a broad array of test services, from general bloodwork to anatomic pathology, and urine toxicology. Specific capabilities include STAT blood testing, qualitative drug screening, genetic testing, urinary testing, sexually transmitted disease testing and more. Laboratory Services has developed a premier reputation for customer service and fast turnaround times in the industry. Laboratory Services has completed over 450,000 tests since inception, operates with 2021 unaudited annual revenue in excess of $25Mn and has two locations in California.
David Jin, M.D., Ph.D., President and Chief Executive Officer of Avalon, commented, "This is a transformative acquisition for Avalon as it brings significant revenue and positive cash flow and is expected to be highly accretive to earnings while adding strong clinical synergies to the existing Avalon portfolio. Laboratory Services has an impressive history of growth and is an established leader within the highly fragmented market for lab testing and services. Laboratory Services' diagnostic business is highly synergistic with our existing precision companion diagnostic business and cellular technology platforms."
"We are delighted to welcome Sarah Cox, Co-founder and CEO of Laboratory Services, and the entire Laboratory Services team to Avalon. Sarah and her team have a proven track record and tremendous reputation within the industry," concluded Dr. Jin.
Sarah Cox, Co-Founder and CEO of Laboratory Services, further noted, "We could not be more excited to join forces with Avalon, as we share a common culture and commitment to putting the patient's needs first. We have become a one stop shop for most clinical testing and each client is provided white glove treatment. We believe that the combination of our established infrastructure with Avalon's resources, as well as cutting edge diagnostic and immune-therapy platform, is expected to establish Avalon as a formidable force in this rapidly growing industry."
Read the full article here.
No. 2 ALBT Potential Catalyst - A Low Float Could Allow For Daily Volatility
According to the Yahoo Finance website, ALBT has a low float.
The website reports this profile to have approximately 32.21Mn shares in its float.
Why is that important? It's important on one crucial level. Volatility.
Could more positive company news before the end of the year help provide a near term spark?
No. 3 ALBT Potential Catalyst - An Explosive Chart History Of Massive Short Term Moves
To put it simply, ALBT's has a chart history full of explosive short term moves.
Here's a quick list of times where ALBT made a wild move:
#1. From a July 21st low of $.4225, ALBT made a move to a high of $.8050 two weeks late on August 4th. Boom. 90% just like that.
#2. That was followed up soon after by a move from September 26th low of $.42 to a September 30th high of $.79. That's 88% in less than a week.
#3. ALBT blazed a path from a low of $.38 on November 1st to a high of $.595 on November 4th. Wow. 56% in a blink.
#4. Most recently, ALBT rocketed from a December 9th low of $.30 to a December 13th high of $.4866. That's 62% in a handful of days.
Explosive. Short term. Mover.
No. 4 ALBT Potential Catalyst - Company Receives Notice Of Allowance Related To QTY Protein Platform
Avalon GloboCare Receives Allowance for Joint U.S. Patent
Jointly with MIT, the Company also Submitted a New U.S. Patent Application for QTY Glucose Transporters
FREEHOLD, N.J., Sept. 29, 2022 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp., a leading global developer of innovative cell-based technologies and therapeutics, today provided an update regarding the Company’s intellectual property portfolio featuring its QTY protein code technology.
The Company received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) related to its QTY fusion water-soluble receptor protein platform. The patent was jointly filed with Dr. Shuguang Zhang of the Massachusetts Institute of Technology (MIT) and covers seven claims related to the technology.
The Company also submitted a new patent application to the USPTO related to its QTY glucose transporter technology. This patent application was also jointly filed with Dr. Shuguang Zhang of MIT. QTY glucose transporters are deregulated in many tumor types and are potentially important targets for cancer therapy.
The “QTY Code,” is a breakthrough technology that can turn difficult to work with water-insoluble transmembrane receptor proteins into water-soluble proteins, enabling their potential use in many clinical applications, including drug development.
Avalon’s proprietary AVA-Trap™ technology utilizes the artificial intelligence (AI) enhanced QTY Code technology to turn receptor molecules into antibody-like decoy receptors that are able to mop up cytokines and chemokines, which are excessively produced during pathological conditions, such as CV-19 and cancer metastasis.
“We continue to strengthen our IP portfolio as we believe our novel QTY code protein design technology holds great potential for biotechnology applications and could generate significant clinical advancements in cellular immunotherapy and immune-oncology,” said David Jin, M.D., Ph.D., President and Chief Executive Officer of Avalon. “Our AI-enhanced protein design QTY Code technology co-developed with MIT’s Dr. Zhang is a novel platform that produces water-soluble proteins for a wide spectrum of biomedical applications including the design and construction of novel targets for application in cellular immunotherapy.”
“We are also pleased to submit a new patent application to the USPTO related to QTY glucose transporters, which are important cancer therapy targets. We believe using the QTY technology will accelerate our understanding of these proteins and the development of antibodies against them to treat cancer,” said Dr. Jin.
Read the full article here.
ALBT Recap: These Potential Catalysts Could Fuel A Vertical Move For This Nasdaq Profile
No. 1 - Signing Of Game-Changing, Transformative Definitive Agreement For Acquisition
No. 2 - A Low Float Could Allow For Daily Volatility
No. 3 - An Explosive Chart History Of Massive Short Term Moves
No. 4 - Company Receives Notice Of Allowance Related To QTY Protein Platform
Coverage is officially reinitiated on ALBT. When time permits, do this: